Information Provided By:
Fly News Breaks for March 3, 2015
ICPT
Mar 3, 2015 | 07:35 EDT
RBC Capital believes that Intercept will rally 20% or more if GenFit data, expected to be announced in the second half of March, isn't clean. If the GenFit data is positive, Intercept's stock might drop, but it would probably rebound, since the company would probably reach a deal with the FDA on a Phase III trial of its OCA drug soon thereafter, according to the firm. RBC keeps a $490 price target and Outperform rating on Intercept.
News For ICPT From the Last 2 Days
There are no results for your query ICPT
I agree to the thefly.com's disclaimer & terms of use
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.


TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.